EHA 2020

2020-06-11 - 2020-06-21
Online, Virtual

ESH 2020

2020-05-29 - 2020-06-01
Online, Virtual

ASH 2019

2019-12-07 - 2019-12-10
Orlando, United States

EHA 2019

2019-06-13 - 2019-06-16
Amsterdam, Netherlands

EMMA 2019

2019-01-31 - 2019-02-02
Vienna, Austria

ASH 2018

2018-12-01 - 2018-12-04
San Diego, United States

EHA 2018

2018-06-14 - 2018-06-17
Stockholm, Sweden

ASH 2017

2017-12-09 - 2017-12-12
Atlanta, United States

EHA 2017

2017-06-22 - 2017-06-25
Madrid, Spain
Search in Scientific Content:
Date
Filters:
Ravulizuma
9:11

Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study

Presenter: Anita Hill
EHA 2020
How to tre
11:54

How to treat patients in COVID-19 pandemic with hypertension condition?

Presenter: Anna F. Dominiczak
ESH 2020
Primary An
2:48

Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
ASH 2019
Novelties
11:01

Novelties on the treatment of non-Hodgkin lymphoma

Presenter: Umberto Vitolo
ASH 2019
Inhibition
4:46

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
ASH 2019
The QUAZAR
4:41

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Presenter: Andrew H. Wei
ASH 2019
LBA-5 Vali
3:58

LBA-5 Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: Robert M. Rifkin
ASH 2019
Clinical I
7:02

Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix Trial

Presenter: Wyndham Wilson
ASH 2019
Special Ed
4:53

Special Education Session on ASH Clinical Practice Guidelines on Venous Thromboembolism

Presenter: Adam Cuker
ASH 2019
Novelties
6:35

Novelties on the treatment of follicular lymphoma

Presenter: Kai Hübel
ASH 2019
A Multicen
3:39

A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia

Presenter: Kerry A Rogers
ASH 2019
Evaluating
3:01

Evaluating Luspatercept Responders in the Phase 3, Randomized, Double-Blind, Placebo-Controlled BELIEVE Trial of Luspatercept in Adult Beta-Thalassemia Patients (Pts) Who Require Regular Red Blood Cell (RBC) Transfusions

Presenter: Vip Viprakasit
ASH 2019
Treatment
3:52

Treatment of multiple myeloma

Presenter: Shaji Kumar
ASH 2019
Phase II T
3:10

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Presenter: Leon Bernal-Mizrachi
ASH 2019
Targeting
3:43

Targeting Apoptosis in Myeloma

Presenter: Wee-Joo Chng
ASH 2019
Lower Risk...
7:32

Lower Risk MDS – Transfusion Dependence

Presenter: Agnieszka Pluta
ASH 2019
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Presenter: Andrew H. Wei
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Perioperat
7:20

Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study: A Perioperative Management Plan for Patients with Atrial Fibrillation Who Are Receiving a Direct Oral Anticoagulant

Presenter: James Douketis
Safety and
12:01

Safety and Efficacy of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis

Presenter: Franco Locatelli
A Randomiz
5:32

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)

Presenter: Tait D. Shanafelt
Phase 3 Ra
6:37

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

Presenter: Thierry Facon
Acquisitio
5:45

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Presenter: Piers Blombery
Best of AS
39:04

Best of ASH

Presenter: John D. Crispino
Long Term
5:48

Long Term Follow-up after SCRI-CAR19v1 Reveals Late Recurrences As Well As a Survival Advantage to Consolidation with HCT after CAR T Cell Induced Remission

Presenter: Corinne Summers
A Personal
6:14

A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes

Presenter: Aziz Nazha
Initial Re
6:41

Initial Report of the Beat AML Umbrella Study for Previously Untreated AML: Evidence of Feasibility and Early Success in Molecularly Driven Phase 1 and 2 Studies

Presenter: Amy Burd
Multicente
8:43

Multicenter Microbiota Analysis Indicates That Pre-HCT Microbiota Injury Is Prevalent across Geography and Predicts Poor Overall Survival

Presenter: Jonathan U. Peled
Rivaroxaba
11:08

Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI)

Presenter: Alok A. Khorana